1
TÍTULO: The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence
AUTORES: Luis, Mariana; Boers, Maarten; Saag, Ken; Buttgereit, Frank; da Silva, Jose A. P.;
PUBLICAÇÃO: 2022, FONTE: CURRENT OPINION IN RHEUMATOLOGY, VOLUME: 34, NÚMERO: 3
INDEXADO EM: WOS
2
TÍTULO: The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence
AUTORES: Luís, M; Boers, M; Saag, K; Buttgereit, F; da Silva, JAP;
PUBLICAÇÃO: 2022, FONTE: Current opinion in rheumatology, VOLUME: 34, NÚMERO: 3
INDEXADO EM: Scopus
3
TÍTULO: Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis
AUTORES: Santiago, T; Jacobs, JW; Saag, KG; Buttgereit, F; Pereira da Silva, JAP;
PUBLICAÇÃO: 2015, FONTE: ACTA REUMATOLOGICA PORTUGUESA, VOLUME: 40, NÚMERO: 1
INDEXADO EM: Scopus WOS
4
TÍTULO: Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
AUTORES: van der Goes, MC; Jacobs, JWG; Boers, M; Andrews, T; Blom Bakkers, MAM; Buttgereit, F; Caeyers, N; Choy, EH; Cutolo, M; Da Silva, JAP; Guillevin, L; Holland, M; Kirwan, JR; Rovensky, J; Saag, KG; Severijns, G; Webber, S; Westhovens, R; Bijlsma, JWJ;
PUBLICAÇÃO: 2010, FONTE: ANNALS OF THE RHEUMATIC DISEASES, VOLUME: 69, NÚMERO: 6
INDEXADO EM: Scopus WOS CrossRef
5
TÍTULO: EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
AUTORES: Hoes, JN; Jacobs, JWG; Boers, M; Boumpas, D; Buttgereit, F; Caeyers, N; Choy, EH; Cutolo, M; Da Silva, JAP; Esselens, G; Guillevin, L; Hafstrom, I; Kirwan, JR; Rovensky, J; Russell, A; Saag, KG; Svensson, B; Westhovens, R; Zeidler, H; Bijlsma, JWJ;
PUBLICAÇÃO: 2007, FONTE: ANNALS OF THE RHEUMATIC DISEASES, VOLUME: 66, NÚMERO: 12
INDEXADO EM: Scopus WOS CrossRef
6
TÍTULO: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
AUTORES: Da Silva, JAP; Jacobs, JWG; Kirwan, JR; Boers, M; Saag, KG; Ines, LBS; de Koning, EJP; Buttgereit, F; Cutolo, M; Capell, H; Rau, R; Bijlsma, JWJ;
PUBLICAÇÃO: 2006, FONTE: ANNALS OF THE RHEUMATIC DISEASES, VOLUME: 65, NÚMERO: 3
INDEXADO EM: Scopus WOS CrossRef
7
TÍTULO: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids - A randomized, double-blind, placebo-controlled extension trial  Full Text
AUTORES: Adachi, JD; Saag, KG; Delmas, PD; Liberman, UA; Emkey, RD; Seeman, E; Lane, NE; Kaufman, JM; Poubelle, PEE; Hawkins, F; Correa Rotter, R; Menkes, CJ; Rodriguez Portales, JA; Schnitzer, TJ; Block, JA; Wing, J; McIlwain, HH; Westhovens, R; Brown, J; Melo Gomes, JA; Gruber, BL; Yanover, MJ; Leite, MOR; Siminoski, KG; Nevitt, MC; Sharp, JT; Malice, MP; Dumortier, T; Czachur, M; Carofano, W; Daifotis, A; ...Mais
PUBLICAÇÃO: 2001, FONTE: ARTHRITIS AND RHEUMATISM, VOLUME: 44, NÚMERO: 1
INDEXADO EM: WOS CrossRef
8
TÍTULO: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
AUTORES: Saag, KG; Emkey, R; Schnitzer, TJ; Brown, JP; Hawkins, F; Goemaere, S; Thamsborg, G; Liberman, UA; Delmas, PD; Malice, MP; Czachur, M; Daifotis, AG; Lane, N; Correa Rotter, R; Yanover, M; Westhovens, R; Epstein, S; Adachi, JD; Poubelle, P; Melo Gomes, J; Rodriguez Portales, JA; ...Mais
PUBLICAÇÃO: 1998, FONTE: New England Journal of Medicine, VOLUME: 339, NÚMERO: 5
INDEXADO EM: Scopus CrossRef